US pharmaceutical firm Moderna plans to submit data from clinical trials of its coronavirus vaccine among children to Japan's health ministry as early as next month.
The trials are underway overseas on subjects aged between 12 and 17.
Moderna CEO Stephane Bancel revealed the plan on Friday in an interview with NHK. Earlier in the day, the health ministry approved the vaccine for use among people aged 18 or older.
Bancel stressed the need to protect young generations in Japan. He said he hopes the Moderna vaccine can soon help people in Japan return to normal life.
The company is in discussions with the Japanese government about supplying 50 million doses next year.
Bancel also referred to a plan to manufacture the vaccine in Japan. He said it would take a few years to build a factory, but his company will be discussing the matter with authorities.